across the portfolio,led by the strong commercial momentum of Nemluvio®as well as the ramp-up of multiple launches in flagship brands across Injectable Aesthetics and Dermatological Skincare

Reinforced scientific leadership in dermatology,presenting new long-term data on Nemluvio, nine-month data on Restylane®and Sculptra®showing sustained results in addressing facial changes from medication-driven weight loss, and continuing investment in market-leading education

Raising 2025 full-year guidance,on net sales to +17.0-17.7% year-on-year growth at constant currency (previously +12-14%) and on Core EBITDA margin to 23.1-23.6% at constant currency (previously approximately 23%) based on the strong growth trajectory across the portfolio and especially of Nemluvio


“Galderma’s strong performance in the first nine months of 2025 demonstrates the breadth of our portfolio and our ability to deliver growth through innovation, commerc
=*=*=*=*=*=
当前为第2/31页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页